Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BICO & VITK -- Ignore unavailable to you. Want to Upgrade?

To: Tom R. Jones who wrote (2135)	9/2/1998 9:34:00 AM
From: Chris Pensinger	Read Replies (1) \| Respond to of 2395

Sold Four! Wednesday September 2, 9:02 am Eastern Time Company Press Release SOURCE: Biocontrol Technology, Inc. Biocontrol Subsidiary, Diasense, Inc., Sells First Diasensors PITTSBURGH, Sept. 2 /PRNewswire/ -- Biocontrol Technology, Inc. (Nasdaq: BICO - news) subsidiary Diasense, Inc. today announced that four orders for the Diasensor(R)1000 have already been received. Two of the devices have been delivered to the teenagers who will use the world's first noninvasive glucose sensors, and two will soon be on their way to help other diabetics. The devices, which recently received European marketing approval (indicated by the CE Mark), were sold to Diasense distributor EuroSurgical Ltd. to fill orders in the United Kingdom, the first market opened for the Diasensor. The Diasensor is priced for European sale at US$9,000. In cooperation with Diasense, Biocontrol personnel recently traveled to the UK to participate in the first device sales and to begin to educate and establish a network of clinicians, health care professionals, and diabetic associations in the UK. EuroSurgical Director, George Cranstone, and Dr. Patrick Cooper, of Biocontrol, presented clinical data from the CE Mark clinical trial and discussed the use of the Diasensor at The Royal Free Hospital in London, the UK Medical Device Agency, and the British Diabetic Association. Although no approval other than the CE Mark is needed to market the Diasensor in the 15-member European Union, these groups were visited at their request to begin the process of information dissemination on this leading edge noninvasive technology. Biocontrol Technology, Inc. (www.bico.com) has its corporate offices in Pittsburgh, PA, and is involved in the development and manufacture of biomedical devices and environmental products. Also located in Pittsburgh, PA, Diasense is a subsidiary of Biocontrol Technology and owns the patent, marketing and distribution rights to the sensor. Biocontrol has the exclusive rights to the research and development and manufacturing of the sensor. This press release contains forward looking statements and shareholders and potential investors are cautioned that such statements are predictions and actual events or results may vary significantly. SOURCE: Biocontrol Technology, Inc.